MX388815B - Inhibidores de il-8 para usarse en el tratamiento de neuropatia periferica inducida por quimioterapia. - Google Patents

Inhibidores de il-8 para usarse en el tratamiento de neuropatia periferica inducida por quimioterapia.

Info

Publication number
MX388815B
MX388815B MX2018008614A MX2018008614A MX388815B MX 388815 B MX388815 B MX 388815B MX 2018008614 A MX2018008614 A MX 2018008614A MX 2018008614 A MX2018008614 A MX 2018008614A MX 388815 B MX388815 B MX 388815B
Authority
MX
Mexico
Prior art keywords
chemotherapy
treatment
inhibitors
peripheral neuropathy
induced peripheral
Prior art date
Application number
MX2018008614A
Other languages
English (en)
Spanish (es)
Other versions
MX2018008614A (es
Inventor
Laura Brandolini
Marcello Allegretti
Pier Adelchi Ruffini
Original Assignee
Dompe Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP16151618.2A external-priority patent/EP3192504A1/en
Application filed by Dompe Farm Spa filed Critical Dompe Farm Spa
Publication of MX2018008614A publication Critical patent/MX2018008614A/es
Publication of MX388815B publication Critical patent/MX388815B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2018008614A 2016-01-15 2017-01-13 Inhibidores de il-8 para usarse en el tratamiento de neuropatia periferica inducida por quimioterapia. MX388815B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16151618.2A EP3192504A1 (en) 2016-01-15 2016-01-15 Il-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy
EP16190871 2016-09-27
PCT/EP2017/050637 WO2017121838A1 (en) 2016-01-15 2017-01-13 Il-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy

Publications (2)

Publication Number Publication Date
MX2018008614A MX2018008614A (es) 2018-11-19
MX388815B true MX388815B (es) 2025-03-20

Family

ID=57906595

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018008614A MX388815B (es) 2016-01-15 2017-01-13 Inhibidores de il-8 para usarse en el tratamiento de neuropatia periferica inducida por quimioterapia.

Country Status (23)

Country Link
US (2) US12268671B2 (enExample)
EP (1) EP3402474B1 (enExample)
JP (1) JP7049254B2 (enExample)
KR (1) KR102737378B1 (enExample)
CN (1) CN108463219B (enExample)
AU (1) AU2017207850B2 (enExample)
CA (1) CA3009438A1 (enExample)
CY (1) CY1125297T1 (enExample)
DK (1) DK3402474T3 (enExample)
ES (1) ES2893701T3 (enExample)
HR (1) HRP20211527T1 (enExample)
HU (1) HUE056606T2 (enExample)
IL (1) IL260373B (enExample)
LT (1) LT3402474T (enExample)
MA (1) MA43861A (enExample)
MX (1) MX388815B (enExample)
PL (1) PL3402474T3 (enExample)
RS (1) RS62427B1 (enExample)
SG (1) SG11201804484YA (enExample)
SI (1) SI3402474T1 (enExample)
SM (1) SMT202100571T1 (enExample)
WO (1) WO2017121838A1 (enExample)
ZA (1) ZA201803486B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101914358B1 (ko) * 2017-01-18 2018-11-02 현대로템 주식회사 실내등 제어회로 및 이를 포함하는 철도차량
CN111343973A (zh) * 2017-10-24 2020-06-26 多姆皮制药公司 用于治疗一些肉瘤的il-8抑制剂
EP3476390A1 (en) 2017-10-24 2019-05-01 Dompé farmaceutici S.p.A. Il-8 inhibitors for use in the treatment of sarcomas
EP3498269A1 (en) * 2017-12-12 2019-06-19 Dompé farmaceutici S.p.A. C5ar inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain
CA3196979A1 (en) * 2020-11-05 2022-05-12 Icahn School Of Medicine At Mount Sinai Cxcr1/cxcr2 inhibitors for use in treating myelofibrosis
EP4052702A1 (en) * 2021-03-04 2022-09-07 Dompé farmaceutici S.p.a. Cxcl8 inhibitor and pharmaceutical composition thereof for use in the treatment of seizures
EP4397305A1 (en) * 2023-01-05 2024-07-10 Dompe' Farmaceutici S.P.A. Cxcl8 inhibitors for use in the treatment of ocular mucous membrane pemphigoid and/or oral mucous membrane pemphigoid

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1303249B1 (it) 1998-10-23 2000-11-06 Dompe Spa Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
HRP20090681T1 (hr) 2004-03-23 2010-02-28 Dompe' S.P.A. Derivati 2-fenilpropionske kiseline i farmaceutski pripravci koji ih sadrže
EP2066335A4 (en) * 2006-09-26 2010-01-20 Univ Case Western Reserve ZYTOKINSIGNALISIERUNG
EP2166006A1 (en) 2008-09-18 2010-03-24 Dompe' S.P.A. 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them
CR20160557A (es) 2014-05-29 2017-01-20 Glaxosmithkline Ip Dev Ltd Compuestos derivados de 1-(ciclopent-2-en-1-il)-3-(2-hidroxi-3-(arilsulfonil)fenil)urea como inhibidores cxcr2
KR20170036753A (ko) * 2014-07-31 2017-04-03 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 화학요법 유도된 말초 신경병증 (cipn)의 예방 및/또는 치료를 위한 cxcr2 길항제의 용도

Also Published As

Publication number Publication date
US12268671B2 (en) 2025-04-08
MX2018008614A (es) 2018-11-19
CN108463219A (zh) 2018-08-28
CA3009438A1 (en) 2017-07-20
US20250195479A1 (en) 2025-06-19
EP3402474A1 (en) 2018-11-21
SI3402474T1 (sl) 2021-12-31
AU2017207850A1 (en) 2018-06-21
SMT202100571T1 (it) 2021-11-12
BR112018013570A2 (pt) 2018-12-11
ES2893701T3 (es) 2022-02-09
DK3402474T3 (da) 2021-10-11
LT3402474T (lt) 2021-11-25
MA43861A (fr) 2021-05-05
PL3402474T3 (pl) 2021-12-27
KR20180101390A (ko) 2018-09-12
HRP20211527T1 (hr) 2021-12-24
RS62427B1 (sr) 2021-11-30
SG11201804484YA (en) 2018-07-30
CY1125297T1 (el) 2023-03-24
AU2017207850B2 (en) 2022-06-30
ZA201803486B (en) 2019-09-25
NZ743344A (en) 2024-05-31
WO2017121838A1 (en) 2017-07-20
US20190015391A1 (en) 2019-01-17
JP2019501948A (ja) 2019-01-24
CN108463219B (zh) 2021-09-17
EP3402474B1 (en) 2021-07-21
JP7049254B2 (ja) 2022-04-06
HUE056606T2 (hu) 2022-02-28
IL260373B (en) 2021-03-25
KR102737378B1 (ko) 2024-12-04

Similar Documents

Publication Publication Date Title
MX2022000711A (es) Inhibidores de parp1.
CY1123557T1 (el) Συνθεσεις και μεθοδοι για την αναστολη της δραστηριοτητας της αργινασης
MX2018008614A (es) Inhibidores de il-8 para usarse en el tratamiento de neuropatia periferica inducida por quimioterapia.
JOP20190175A1 (ar) مركبات تعمل كمعدِّل لمستقبل هيدروكربون الأريل (AhR)
CL2017001209A1 (es) Inhibidor de cinasa aurora a
BR112017002060A2 (pt) novo uso
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
JO3653B1 (ar) ترايازول عوامل مساعدة لمستقبل apj
GT201600215A (es) Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4
MX381046B (es) Anticuerpos anti-csf1r e inhibidores de pd-1/pd-l1, y usos de los mismos para el tratamiento de cáncer remisión a las solicitudes relacionadas.
EA201691974A1 (ru) Антитела против ox40 и способы их применения
EA202092435A3 (ru) Моноклональные антитела против bcma
CL2016001911A1 (es) Compuesto heterocíclico fusionado
BR112016018555A8 (pt) Ciclopropilaminas como inibidores de lsd1, seu uso, composição farmacêutica que os compreende e método de inibição de lsd1
EA201890810A1 (ru) Соединения, эффективные для лечения гепатотоксичности и стеатоза печени, и их применение
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
DOP2016000312A (es) Compuestos derivados de 1-(ciclopent-2-en-1-il)-3-(2-hidroxi-3-(arilsulfonil)fenil)urea como inhibidores cxcr2
MX373320B (es) Compuestos inhibidores de pde2.
EA201692470A1 (ru) Фармацевтические комбинации
UY38352A (es) Inhibidores de integrina alfavbeta6
MX2019001781A (es) Compuestos de tiofeno condensado utiles como inhibidores de napi-iib.
MX379289B (es) Uso de agonistas del receptor nicotinico de acetilcolina alfa 7.
CY1125437T1 (el) Αναστολεις της il-8 προς χρηση στη θεραπεια ορισμενων ουρολογικων διαταραχων
EA201990064A1 (ru) Противомалярийные композиции и варианты их применения
CL2016002354A1 (es) Compuestos derivados de benzamida con actividad inhibidora de wnt; compuestos intermediarios; composicion farmaceutica que los comprende; uso en el tratamiento del cancer y otras enfermedades con respuesta inmune inapropiada.